GoodRx(GDRX)

Search documents
GoodRx(GDRX) - 2023 Q3 - Earnings Call Presentation
2023-11-09 12:34
Scale our pharma manufacturer solutions efforts Scott Wagner Interim CEO Meaningful progress made against top priorities in Q3 1 2 3 4 Make sure we have the strongest network relationships and retail pharmacy strategy possible Hone our short- and medium-term growth plans for the core prescription transactions offering and align our teams and resources behind it November 9, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litig ...
GoodRx(GDRX) - 2023 Q3 - Quarterly Report
2023-11-08 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip Code) o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 _____________________ ...
GoodRx(GDRX) - 2023 Q2 - Earnings Call Transcript
2023-08-09 17:10
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q2 2023 Earnings Conference Call August 9, 2023 8:00 AM ET Company Participants Scott Wagner - Interim CEO Karsten Voermann - CFO Raj Beri - COO Whitney Notaro - VP, IR Conference Call Participants Charles Rhyee - TD Cowen Jonathan Yong - Credit Suisse Jailendra Singh - Truist Securities George Hill - Deutsche Bank Stan Berenshteyn - Wells Fargo Securities, LLC Sandy Draper - Guggenheim Securities, LLC Daniel Grosslight - Citigroup Jian Li - Evercore ISI McCoy Madson - Mo ...
GoodRx(GDRX) - 2023 Q2 - Earnings Call Presentation
2023-08-09 11:47
Key Operating Metrics We exited the second quarter of 2023 with over 7 million prescription-related consumers that used GoodRx across our prescription transactions and subscription offerings. Our prescription-related consumers represent the sum of Monthly Active Consumers for the three months ended June 30, 2023 and subscribers to our subscription plans as of June 30, 2023. Each subscription plan may represent more than one subscriber since family subscription plans may include multiple members. Earnings Pr ...
GoodRx(GDRX) - 2023 Q2 - Quarterly Report
2023-08-08 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 _________________________ ...
GoodRx(GDRX) - 2023 Q1 - Earnings Call Transcript
2023-05-10 18:51
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET Company Participants Aubrey Reynolds - Senior Manager Investor Relations Doug Hirsch - Chief Mission Officer Trevor Bezdek - Chairman Karsten Voermann - Chief Financial Officer Scott Wagner - Interim Chief Executive Officer Conference Call Participants Stephanie Davis - SVB Leerink Sandy Draper - Guggenheim Charles Rhyee - Cowen Jian Li - Evercore ISI Michael Cherny - Bank of America Stan Berenshteyn - Wells Fargo ...
GoodRx(GDRX) - 2023 Q1 - Quarterly Report
2023-05-09 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5104396 (State or o ...
GoodRx(GDRX) - 2022 Q4 - Earnings Call Transcript
2023-03-01 03:37
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Representatives Doug Hirsch - Co-Founders, Co-Chief Executive Officer Trevor Bezdek - Co-Founders, Co-Chief Executive Officer Karsten Voermann - Chief Financial Officer Aubrey Reynolds - Senior Investor Relations Manager Conference Call Participants Mark Mahaney - Evercore ISI Mitchell Kellett - Guggenheim Lucas Romanski - Cowen Michael Cherny - Bank of America Craig Hettenbach - Morgan Stanley Eric She ...
GoodRx(GDRX) - 2022 Q4 - Earnings Call Presentation
2023-02-28 22:23
| --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------- ...
GoodRx(GDRX) - 2022 Q4 - Annual Report
2023-02-28 16:00
Revenue and Financial Performance - Revenue for the year ended December 31, 2022, grew 3% to $766.6 million from $745.4 million in 2021[304] - Net loss for 2022 was $32.8 million, with a net loss margin of 4.3%, compared to a net loss of $25.3 million and a margin of 3.4% in 2021[304] - Adjusted EBITDA for 2022 was $213.5 million, with an Adjusted EBITDA Margin of 27.8%, down from $229.6 million and 30.8% in 2021[304] - The estimated impact of the "grocer issue" on prescription transactions revenue in 2022 was approximately $110.0 million to $120.0 million[302] - Prescription transactions revenue decreased by $42.8 million, or 7%, year-over-year, primarily due to a 2% decrease in average Monthly Active Consumers[323] Consumer Metrics - Monthly Active Consumers for December 2022 were reported at 5.9 million, reflecting a decline due to the grocer issue[309] - Subscription plans as of December 31, 2022, totaled 1,030,000, down from 1,210,000 in December 2021[311] - The company expects continued adverse impacts on prescription transactions revenue and Monthly Active Consumers due to ongoing consumer response uncertainties[302] Revenue Streams - Pharma manufacturer solutions revenue is expected to grow as a percentage of total revenue in the near to medium term[318] - Pharma manufacturer solutions revenue increased by $26.1 million, or 36%, year-over-year, driven by organic growth and the acquisition of vitaCare, contributing $5.6 million in 2022[324] - Subscription revenue increased by $36.2 million, or 60%, year-over-year, despite a 15% decrease in the number of subscription plans to 1,030 thousand[325] Costs and Expenses - Cost of revenue increased by $18.4 million, or 39%, year-over-year, primarily due to increased personnel costs and fulfillment costs related to the vitaCare acquisition[328] - Product development and technology expenses increased by $17.3 million, or 14%, year-over-year, driven by higher payroll costs due to increased headcount[329] - Sales and marketing expenses decreased by $12.6 million, or 3%, year-over-year, primarily due to a $69.9 million decrease in advertising expenses[330] - General and administrative expenses decreased by $9.9 million, or 6%, year-over-year, mainly due to a decrease in stock-based compensation expense[331] - Depreciation and amortization expenses increased by $19.6 million, or 57%, year-over-year, primarily due to higher capitalized software amortization[332] Cash Flow and Investments - GoodRx Holdings, Inc. reported a net cash provided by operating activities of $146.78 million for the year ended December 31, 2022, a decrease of $32.0 million compared to $178.78 million in 2021[341] - The net cash used in investing activities increased by $31.8 million in 2022, totaling $210.50 million, primarily due to a $27.6 million increase in cash paid for acquisitions and a $21.4 million increase in software development costs[343] - Net cash used in financing activities rose by $89.7 million in 2022, amounting to $120.23 million, largely driven by $101.7 million for repurchases of Class A common stock[344] - The company reported a net cash change of $(183.94) million in cash, cash equivalents, and restricted cash for 2022, compared to $(30.48) million in 2021[341] Interest and Taxation - Interest income increased by $9.2 million year-over-year, primarily due to higher interest rates on cash equivalents[333] - As of December 31, 2022, GoodRx Holdings, Inc. maintained a full valuation allowance of $57.1 million against its net deferred tax assets in excess of amortizable goodwill[359] - A hypothetical 100 basis point increase in interest rates would have increased GoodRx's interest expense by $6.8 million for the year ended December 31, 2022[363] Economic Conditions - GoodRx Holdings, Inc. does not believe inflation has had a material effect on its business, but acknowledges potential risks if costs become subject to significant inflationary pressures[364]